Dr. McGarrity noted that there was a procedure for holding a 
closed meeting, but that it had to be announced in the Federal 
Register within the proscribed notification period. Such a 
procedure may be used in the future for more complicated 
proposals so that they can be handled expeditiously. He then 
recessed the Committee for lunch, to reconvene at 1:45 p.m. , the 
same day. 
Dr. McGarrity opened the afternoon session by once again thanking 
the Human Gene Therapy Subcommittee for its time and dedication 
in reviewing the human gene transfer proposal. Mr. Brewer added 
that he believed the result of the deliberations on the human 
gene transfer proposal showed a balance of the concerns on all 
sides of the issues. He said he didn't consider the decision 
precedent-setting in any way, and he viewed it as a stand-alone 
case reviewed on its merits. He noted that in the future there 
will be proposals that will be more complex and will require the 
kind of scrutiny exhibited in the Subcommittee and at this 
meeting. 
Dr. McGarrity then called on Dr. Cohen to present the next agenda 
item. 
IV. PROPOSED AMENDMENT OF SECTION I-C OF THE NIH GUIDELINES (TABS 
1332/1, 1334, 1338): 
Dr. Cohen began by restating the history of the proposed 
amendment. He said Mr. Jeremy Rif kin of the Foundation on 
Economic Trends proposed a revision to the NIH Guidelines after 
the controversy concerning the Wistar Institute's rabies vaccine 
field test in Argentina. This proposal was considered at the 
September, 1987 RAC meeting. As a result, a working group was 
established to develop a proposal. Dr. Cohen said the Working 
Group on International Projects met on February 1, 1988, and 
developed a proposal that was considered by the RAC on June 3, 
1988. At that time, it was referred back to the Working Group 
for additional discussion and revision. The Working Group met on 
August 15, 1988, and recommended the following proposal (tab 
1338) : 
"The NIH Guidelines are also applicable to recombinant 
DNA projects done abroad: 
"1. If they are supported by NIH funds; or 
"2. If they involve deliberate release into 
the environment or testing in humans of 
materials containing recombinant DNA 
developed with NIH funds, and if the 
[ 254 ] 
Recombinant DNA Research, Volume 13 
